Ítem
Solo Metadatos

Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis

Mostrar el registro sencillo de la publicación
dc.creatorNavas, Carlosspa
dc.creatorTorres-Duque, Carlos Aspa
dc.creatorMunoz-Ceron, Joespa
dc.creatorAlvarez, Carlos E.
dc.creatorGarcía, Juan Rspa
dc.creatorZarco, Luisspa
dc.creatorVélez, Lázaro Aspa
dc.creatorAwad, Carlosspa
dc.creatorCastro, Carlos
dc.date.accessioned2020-06-11T13:20:54Z
dc.date.available2020-06-11T13:20:54Z
dc.date.created2018-01spa
dc.description.abstractBackground: Multiple sclerosis is an inflammatory and neurodegenerative demyelinating disease. Current treatment of multiple sclerosis focuses on the use of immunomodulatory, immunosuppressant, and selective immunosuppressant agents. Some of these medications may result in high risk of opportunistic infections including tuberculosis.Objective: The purpose of this study was to obtain consensus from a panel of neurologists, pulmonologists, infectious disease specialists, and epidemiology experts regarding the diagnosis, treatment, and monitoring of latent tuberculosis in patients with multiple sclerosis.Methods: A panel of experts in multiple sclerosis and tuberculosis was established. The methodological process was performed in three phases: definition of questions, answer using Delphi methodology, and the discussion of questions not agreed.Results: Tuberculosis screening is suggested when multiple sclerosis drugs are prescribed. The recommended tests for latent tuberculosis are tuberculin and interferon gamma release test. When an anti-tuberculosis treatment is indicated, monitoring should be performed to determine liver enzyme values with consideration of age as well as comorbid conditions such as a history of alcoholism, age, obesity, concomitant hepatotoxic drugs, and history of liver disease.Conclusion: Latent tuberculosis should be considered in patients with multiple sclerosis who are going to be treated with immunomodulatory and immunosuppressant medications. Transaminase level monitoring is required on a periodic basis depending on clinical and laboratory characteristics. In addition to the liver impairment, other side effects should be considered when Isoniazid is prescribed.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1177/2055217317752202
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/24625
dc.language.isoeng
dc.publisherMultiple Sclerosis Journal - Experimental Translational and Clinicalspa
dc.relation.citationIssueNo. 1
dc.relation.citationTitleMultiple Sclerosis Journal - Experimental Translational and Clinical
dc.relation.citationVolumeVol. 4
dc.relation.ispartofMultiple Sclerosis Journal - Experimental Translational and Clinical, ISSN: , Vol.4, No.1 (2018-01); pp. 2055217317752202spa
dc.relation.urihttps://journals.sagepub.com/doi/pdf/10.1177/2055217317752202spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordMedical and Health Sciencesspa
dc.subject.keywordClinical Sciencesspa
dc.titleDiagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosisspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos